Cocrystal pharma reports first quarter 2025 financial results and provides updates on its antiviral drug-development programs

In vitro testing with cdi-988 demonstrated superior broad-spectrum antiviral activity against major norovirus variants bothell, wash., may 15, 2025 (globe newswire) -- cocrystal pharma, inc. (nasdaq: cocp) (“cocrystal” or the “company”) reports financial results for the three months ended march 31, 2025, and provides updates on its antiviral product pipeline, upcoming milestones and business activities.
COCP Ratings Summary
COCP Quant Ranking